OptimizeRx signals $109M-$114M revenue target for 2026 as market shifts drive cautious outlook
Source: SeekingAlpha
2026-03-05 18:46:34 ET
More on OptimizeRx
- OptimizeRx Corporation (OPRX) Q4 2025 Earnings Call Transcript
- OptimizeRx Stock: A Buy-The-Dip Opportunity For This Above-Average Growth Story
- OptimizeRx Non-GAAP EPS of $0.51 beats by $0.29, revenue of $32.2M beats by $1.29M
- Seeking Alpha’s Quant Rating on OptimizeRx
- Historical earnings data for OptimizeRx
Read the full article on Seeking Alpha
For further details see:
OptimizeRx signals $109M-$114M revenue target for 2026 as market shifts drive cautious outlook
OptimizeRx Corporation
NASDAQ: OPRX
OPRX Trading
0.65% G/L:
$6.15 Last:
311,923 Volume:
$6.01 Open:
OPRX Latest News
March 05, 2026 05:04:30 pm
UPDATE - OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
March 05, 2026 04:01:00 pm
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
OPRX Stock Data
$189,855,041
17,596,775
3.29%
31
N/A
Healthcare Providers & Services
Healthcare
US
Waltham
